Item 8.01 Other Events. On January 9, 2026, Iovance Biotherapeutics, Inc. (the “ Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. The Company’s presentation states that the Company expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of Amtagvi sales. A copy of the Company’s presentation that it intends to use at such events is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and (d) Exhibits. Exhibit Description No. ────────────────────────────────────────────────────────────────────── 99.1 Iovance Biotherapeutics, Inc., Corporate Presentation 104 Cover Page Interactive Data File (embedded as SIGNATURES